Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable?
Paolo Carlini(National Cancer Institute), Francesco Cognetti(Apple (Israel)), Francesca Paoloni(Fondazione Gimema Onlus), Alessandra Fabi(Agostino Gemelli University Polyclinic), Enzo Maria Ruggeri, Antonio Frassoldati(Italian Oncology Group of Clinical Research), Paola Papaldo(Cancer Institute (WIA)), Salvatore De Marco(National Cancer Institute), A Casali(National Cancer Institute), M Nardi(National Cancer Institute)
Cited by 43
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
|Blood|2011|460
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394